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Abstract
Deleted in Liver Cancer-1 (DLC1), a member of the RhoGAP family of proteins, functions as
a tumor suppressor in several cancers including breast cancer. However, its clinical rele-
vance is unclear in breast cancer. In this study, expression of DLC1 was correlated with
prognosis using publicly available breast cancer gene expression datasets and quantitative
Reverse Transcription PCR in cohorts of Estrogen Receptor-positive (ER+) breast cancer.
Low expression of DLC1 correlates with poor prognosis in patients with ER+ breast cancer
with further decrease in metastatic lesions. The Cancer Genome Atlas (TCGA) data showed
that down regulation of DLC1 is not due to methylation or mutations. To seek further insights
in understanding the role of DLC1 in ER+ breast cancer, we stably overexpressed DLC1-
full-length (DLC1-FL) in T-47D breast cancer cells; this inhibited cell colony formation signifi-
cantly in vitro compared to its control counterpart. Label-free global proteomic and TiO2
phosphopeptide enrichment assays (ProteomeXchange identifier PXD008220) showed that
205 and 122 phosphopeptides were unique to DLC1-FL cells and T-47D-control cells,
respectively, whereas 6,726 were quantified by phosphoproteomics analysis in both condi-
tions. The top three significant clusters of differentially phosphopeptides identified by DAVID
pathway analysis represent cell-cell adhesion, mRNA processing and splicing, and tran-
scription regulation. Phosphoproteomics analysis documented an inverse relation between
DLC1 expression and several phosphopeptides including epithelial cell transforming
sequence 2 (ECT2). Decreased phosphorylation of ECT2 at the residue T359, critical for its
active conformational change, was validated by western blot. In addition, the ECT2 T359-
containing phosphopeptide was detected in both basal and luminal patient-derived breast
cancers breast cancer phosphoproteomics data on the Clinical Proteomic Tumor Analysis
Consortium (CPTAC) Assay portal. Together, for the first time, this implicates ECT2 phos-
phorylation in breast cancer, which has been proposed as a therapeutic target in lung can-
cer. In conclusion, this data suggests that low expression of DLC1 is associated with poor
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prognosis. Targeting ECT2 phosphopeptides could provide a promising mechanism for con-
trolling poor prognosis seen in DLC1low ER+ breast cancer.
Introduction
Deleted in Liver Cancer 1 (DLC1), encoding a Rho GTPase-activating protein (RhoGAP), was
originally discovered as a gene deleted or downregulated in primary hepatocellular carcinomas
(HCC) [1]. Further studies reported the downregulation of DLC1 in other human cancers
including lung, breast, renal, cutaneous melanomas, nasopharyngeal (NPC), esophageal, cervi-
cal, and prostate cancers [2–7]. DLC1 has been shown to act as a tumor suppressor in a num-
ber of experimental cancer models [8–15]. Recent studies suggest the emerging role of DLC1
as a metastasis suppressor gene in a number of cancers including breast cancer [8]. Restoration
of DLC1 in metastatic breast cancer cells (M4A4), to levels similar to its non-metastatic clone
(NM2C5), inhibited cell migration and invasion in vitro and reduced pulmonary metastases in
athymic mice [16]. Other studies also reported that DLC1 suppresses breast cancer metastasis
to the bone and lung [17, 18]. Overexpression of GATA3, associated with upregulation of
DLC1, significantly decreased the pulmonary metastasis in nude mice [17]. Knockdown of
DLC1 enhanced bone colonization of circulating cancer cells, whereas its restoration signifi-
cantly decreased bone metastasis [18].
The clinical relevance of DLC1 and its potential utility have not been well established in
breast cancer. Here, we report the prognostic and mechanistic relevance of DLC1 restoration
in ER+ breast cancer.
Materials and methods
Analysis of publicly available datasets
Expression of DLC1 was analyzed based on ER-status, molecular subtypes, and other clinico-
pathological parameters using the datasets from the gene expression-based outcome for breast
cancer online algorithm (GOBO)[19]. GOBO is a web-based analysis tool that utilizes 11 pub-
licly available Affymetrix U133A gene expression data curated from 1881 breast cancer
patients with associated stage, grade, nodal status, and intrinsic molecular classification [19].
The distribution of 1881 tumors was as follows: 1) ER positive tumors (n = 1225), 2) ER-nega-
tive tumors (n = 395), 3) systemically untreated patients (n = 927), and 4) patients treated with
tamoxifen alone (n = 326). Clinical characteristics of individual datasets have been described
previously [19]. Association of outcome was investigated for each patient cohort with overall
survival (OS) as endpoint and 10-year censoring in the above groups. The Kaplan-Meier sur-
vival analysis was calculated using Cox proportional hazard model, and the score test of the
proportional hazard model is equivalent to the log-rank test.
Somatic mutation rate, DNA copy number alterations (CNAs), mRNA, and methylation status
for DLC1 were analyzed using the cBioPortal for Cancer Genomics (http://cbioportal.org). The
portal is a Web resource to analyze complex cancer genomics data including genetic, epigenetic,
gene expression and proteomic events [20, 21]. All tumor samples that have CNA and sequencing
data (n = 963 samples) and methylation data (HM450; n = 784 patients) were analyzed.
Patient samples
All protocols were reviewed and approved by the Institutional Review Board of Indiana Uni-
versity. Samples and clinical records were anonymized prior to access by the authors and
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linked with a numerical identifier. The IRB waived requirement of informed consent. All
archival formalin-fixed, paraffin-embedded (FFPE) tumor blocks in this study were from
patients with ER-positive (greater than 1% expression as per ASCO-CAP guidelines) breast
carcinomas at the Indiana University Health Pathology Lab (IUHPL). The quality of each
block and the relative cellular composition were determined by the histopathological assess-
ment of adjacent sections from FFPE tumor blocks.
OncotypeDX samples
Sixty archival FFPE tumor blocks were obtained from patients with ER-positive and node-neg-
ative breast carcinomas at IUHPL based on their Oncotype DX recurrence score (19 low score,
21 intermediate score, and 20 high score). Four of the 60 cases had a lobular histology. Demo-
graphic and clinical characteristics of the patients were acquired from medical charts as
described previously [22].
Primary ER-positive breast tumors and matched lymph node samples
Twenty-three archival FFPE primary human breast tumor blocks and their matched lymph
node metastases were obtained from patients with ER-positive breast carcinomas at the
IUHPL (S1 Table).
RNA isolation and quantitative reverse transcription-PCR (qRT-PCR)
Total RNA was extracted from 10μm-thick sections of archival FFPE blocks using RecoverAll
total nucleic acid isolation kit (Life Technologies, Grand Island, NY). The quality of RNA was
assessed using the Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wal-
tham, MA). Total RNA from breast cancer cell lines was isolated using miRNeasy kit (Qiagen,
Germantown, MD). Total RNA was reverse-transcribed using the high capacity cDNA reverse
transcription kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s
instructions. The mRNA level of DLC1 (Hs00183436_m1) and ECT2 (Hs00978168_m1) was
analyzed by quantitative reverse transcription- PCR (qRT-PCR) using TaqMan gene expres-
sion assays on an ABI Prism 7900 platform (Thermo Fisher Scientific, Waltham, MA) with
ACTB (Hs00357333_g1) and GUSB (Hs99999908_m1) as endogenous controls for normaliza-
tion. All qRT-PCR reactions were performed in duplicates for tumor blocks and triplicates for
breast cancer cell lines. The gene expression values was analyzed according to ΔΔCt method
using the Applied Biosystems DataAssist Software v3.0. GraphPad Prism 7.03 software was
used to analyze statistical significance for qRT-PCR data.
Breast cancer cell lines and generation of stable full-length DLC1
(DLC1-FL) construct
MCF-7, T-47D and ZR75.1 cell lines were purchased from American Type Culture Collection
(ATCC, Manassas, VA). Cell lines have been carefully maintained in a humidified tissue cul-
ture incubator at 37˚C in 5% CO2:95% air atmosphere, and stocks of the earliest passage cells
have been stored. The cell lines were grown in phenol-red–free DMEM containing 5% char-
coal-stripped fetal calf serum (CCS) and 100 mg/mL penicillin at least 4 days before the experi-
ments as described previously [23].
To confirm the functional relevance of DLC1 in ER-positive breast cancer, we overex-
pressed full-length DLC1 (DLC1-FL) in T-47D breast cancer cell line using GenScript’s GenEZ
ORF DLC1 construct (DLC1-FL; NM_182643). GenScript’s GenEZ ORF DLC1-FL was cloned
into mammalian expression cloning vector, pcDNA3.1+/C-(K)-DYK, using the CloneEZ
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cloning technology, according to the manufacturer’s instructions (GenScript, Piscataway, NJ).
Stable cells with the control vector (pcDNA3.1+/C-(K)-DYK vector only) or vector with
DLC1-FL construct were generated in T-47D cells, which lacks DLC1 expression. The colonies
were screened using qRT-PCR (S1 Appendix) and the construct with high DLC1 expression
was chosen for further analysis. Protein expression was also validated using Western blot
assays. Throughout the paper, T-47D cells with control vector and DLC1 overexpression are
named as control and DLC1-FL, respectively.
Clonogenic assay
Control and DLC1-FL cells (200 cells) were plated in triplicates in 6 well plates for 14 days to
assess the cell growth. The media was changed every 3 days. After 14 days, media were aspi-
rated and cells were stained with crystal violet. Cells were permeabilized using citrate buffer
and absorbance was read at 560 nm on a plate reader.
Cell-cycle analysis
Control and DLC1-FL cells (5x105 cells/ml) were plated as described above (breast cancer cell
lines) and harvested at 24 and 48 hours after the attachment of cells, suspended in PBS, and
fixed in 70% ethanol. Then, DNA content was evaluated after propidium iodide staining. Fluo-
rescence-activated cell-sorting analysis was carried out using a FACScan flow cytometer (Beck-
ton Dickinson) and CellQuest software.
Apoptosis assay
The PE Annexin V Apoptosis Detection Kit I (BD Biosciences) was performed by flow cytom-
etry according to the manufacturer’s instructions. Briefly, DLC1-FL and control cells (5x105
cells/ml) were harvested, washed in PBS, and pelleted by centrifugation. Cells were suspended
with 1X binding buffer and then 5 μl Annexin V-fluorescein isothiocyanate was added. After
15 min, 10 μl propidium iodide was added and the suspension was incubated in the dark at
room temperature for 15 min. Binding buffer (1X; 400 μl) was added to the suspension and
was gently vortexed. Cells were analyzed using a FACScan flow cytometer. The numbers show
the percentages of cells in each quadrant (bottom left: intact cells; bottom right: early apoptotic
cells; top left: necrotic cells; top right: late apoptotic or necrotic cells).
Invasion assay
The cell invasion assay was performed using CytoSelect 24 well cell invasion assay. Briefly,
cells were plated in phenol red-free MEM with 5% charcoal stripped fetal calf serum for 48
hours and switched to 1% serum media for 24 hours. Cells were added to the upper chamber
(6000 cells/insert) in serum-free medium. Cell were then allowed to migrate towards the lower
chamber in the presence or absence of Fetal Bovine Serum (20%). After 72 hours, cells on the
underside of the upper chambers were stained using the Cell Invasion Assay Kit (Promega,
Madison, WI, USA) and examined by light microscopy according to the manufacturer’s
instructions.
Rho GTPase activation assay
RhoA activity was assessed with the Rhotekin binding assay as described previously (Cytoskel-
eton, Inc., Denver, CO). Briefly, cells were grown in 100-mm dishes. After serum starvation
for 24 hours, cells were treated either with calpeptin (Rho Activator I; 0.1 mg/ml final) for 30
minutes or with carrier only (DMSO). Cell lysates were incubated with the GST-fused Rho-
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binding domain of Rhotekin immobilized on reduced glutathione-agarose for 2 hours at 4˚C
in a tube rotator and then rinsed. The level of active RhoA and total RhoA was detected by
Western blotting with anti-RhoA antibody.
Label-free quantitative global proteomic and phosphoproteomic analyses
Global proteomic and phosphoproteomic analyses of control and DLC1-FL cells were per-
formed at the Indiana University School of Medicine Proteomics Core facility including cell
extract preparation, protein digestion with LysC/trypsin, enrichment of phosphopeptides, and
analysis via liquid chromatography (LC) coupled with tandem mass spectrometry (MS/MS)
(S1 Fig). Cell pellets were lysed and proteins extracted with 8M urea in Tris-HCl pH 8.0 by
sonication and the resulting supernatants were recovered by centrifugation. The resulting pep-
tides were subjected to reduction with 5mM tris(2-carboxyethyl)phosphine hydrochloride
(TCEP) and alkylated with 10mM chloroacetamide (CAM) prior to digestion with LysC
(Roche) and Trypsin Gold (Promega), as previously described [24–26]. Peptide digestion reac-
tions were cleaned up using a Waters Sep-Pak C18 column. Approximate 5% of the total pep-
tide digestion was aliquoted for global proteomic analysis corresponding to ~50 μg of total
protein. For phosphopeptide analysis, 1,000 μg of protein was phosphoenriched using a TiO2
column (Pierce Phosphoprotein Enrichment kit, Thermo Fisher, Waltham, MA) as per manu-
facturer’s instructions, and were cleaned up on a graphite column [27]. Briefly, ~20–25 μg
digested total peptides or enriched phosphopeptides were injected onto a C18 Easy Spray 50
cm column and eluted with a 3 hour acetonitrile gradient (0–38%) in-line with a Thermo
Orbitrap Velos Pro mass spectrometer [28]. MS1 data was acquired at a resolution of 60,000
with the top fifteen most intense ions selected for MS/MS analysis in the ion trap. Dynamic
exclusion was applied for a 50 second duration. The resulting RAW files were analyzed in
Thermo Proteome Discoverer (PD) 2.2. Database searches were performed with SEQUEST
HT (as a node in PD 2.2) as previously described [26] with a few modifications: trypsin diges-
tion, 2 maximum missed cleavages, precursor mass tolerance of 10 ppm, fragment mass toler-
ance of 0.8 Da, a fixed modification of +57.021 Da (carbamidomethylation) on cysteine, and
variable modifications of +15.995 Da (oxidation) on methionine and +79.966 Da (phosphory-
lation) on serine, threonine, and tyrosine. A reverse database search was performed using
SEQUEST HT to determine the spectral false discovery rate (FDR), and subsequent results
were filtered by an FDR of 1% as previously described [24]. The FASTA database used was a
human proteome downloaded from Uniprot on January 20, 2017 with addition of 73 common
contaminants such as proteases and keratin, yielding a total of 21,010 non-redundant protein
sequences. Prior to quantitation, the Spectrum Files RC node in PD 2.2 was utilized to perform
spectrum recalibration. In addition, the MS1 intensity quantitative tool Minora Feature Detec-
tor was utilized for label-free quantitation for area under the curve calculations for up to the
top three unique plus razor peptides detected per unique protein. Normalization was per-
formed using the total peptide amount to account for random errors. Manual validation of
spectra for phosphopeptides of interest was performed. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium via the PRIDE [29–31] partner
repository with the dataset identifier PXD008220 and 10.6019/PXD008220.
Three biological replicates of control and DLC-FL cells were analyzed by mass spectrometry
for both the global proteomic and the phosphoproteomic analyses in order to provide statisti-
cal rigor. Statistical significance was determined for the global proteome and phosphopeptide
samples during PD 2.2 analysis using an ANOVA (background-based) followed by a Tukey
HSD posthoc test (non-parametric test, which does not assume a normal distribution), and a
p-value less than 0.05 was considered significant. An FDR-corrected p-value< 0.1 was also
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determined using the Benjamini-Hochberg correction. In addition, GO term analysis was per-
formed in DAVID using the Uniprot accession numbers of the parent protein for the signifi-
cantly changed phosphopeptides.
Western blot analysis
Breast cancer cell lines were lysed in radioimmunoassay buffer (RIPA) and equal amounts of
protein were subjected to SDS-PAGE and Western blot analysis in triplicates as described pre-
viously [32]. The Bio-Rad DC-Protein assay kit (Bio-Rad, Hercules, CA) was used to deter-
mine protein concentrations. Blots were incubated with antibodies against DLC1 (Thermo
fisher Scientific, Waltham, MA), ECT2 (EMD Millipore, Burlington, MA), phospho-ECT2
[kind gift of Dr. Alan Fields [33]]. Antibodies against TFF1/pS2, cyclin D1, c-Myc, estrogen
receptor α (ERα) and phospho-ERα (Ser118) were purchased from Cell Signaling Technology
(Danvers, MA). Phospho-specific ECT2 antibody production and validation were described as
previously [33]. Briefly, immunogenic phosphopeptides were: Ac-321CYLYEKANpTPE
LKKSV335-amide and Ac-321YLYEKANpTPELKKSVC335-amide respectively. Antibodies
against GAPDH (GeneTex, Inc., Irvine, CA) and β-actin Sigma (St. Louis, MO) were used as
loading controls. Protein bands were visualized by SuperSignal West Pico PLUS Chemilumi-
nescent Substrate kit (Amersham, Piscataway, NJ) and Amersham Imager 600 GE Healthcare
Life Sciences (GE Healthcare Bio-Sciences, Pittsburgh, PA). The data are representative of
three individual sets.
The Clinical Proteomic Tumor Analysis Consortium (CPTAC)
Published supplementary data from The Clinical Proteomic Tumor Analysis Consortium
(CPTAC) breast cancer phosphoproteomics database [34] was downloaded from the Molecu-
lar and Cellular Proteomics website. Unique phosphopeptide sequences detected in the basal
or luminal breast cancer analyses (performed on a Thermo Q Exactive) were compared to the
sequences detected in this study (performed on a Thermo Velos Pro Orbitrap) to determine
the overlap.
Results
Low expression of DLC1 correlates with poor prognosis in patients with
ER-positive breast cancer
To determine the clinical relevance and prognostic value of DLC1, we first performed in silico
analysis using Gene expression based Outcome for Breast cancer Online (GOBO) tool, which
contains clinico-pathological and Affymetrix gene expression data from 1,881 breast cancer
patients [19]. Of the 560 patients with ER-positive tumors and overall survival data, low
expression of DLC1 (40%) had significantly worse overall survival (OS) (ANOVA; p = 0.002;
Fig 1A); an association was not observed in ER-negative tumors (ANOVA; p = 0.68; data not
shown). Expression levels of DLC1 is especially is critical in patients with lymph node positive
(LNpos) subset (ANOVA; p = 5e-04; Fig 1B), showing that cases with low DLC1 (n = 52% of
215 patients with available data) have a significantly poor survival. This indicates that DLC1 is
prognostic in ER-positive patients and increasing the expression of DLC1 could help to pre-
vent recurrence/metastases.
We next sought to confirm this in silico data in a cohort of patient samples from Indiana
University with Oncotype DX recurrence score as a surrogate marker. This score has been vali-
dated in multiple clinical trials and is used in clinical practice to make treatment decisions [35,
36]. Analysis of the National Surgical Adjuvant Breast and Bowel Project (B14 and B20)
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clinical trials has led to the development of the Oncotype DX recurrence score [35]. The score
estimates the likelihood of disease recurrence in women with early-stage, ER-positive breast
cancer and has been used as a surrogate for predicting outcomes. qRT-PCR analysis of 60
FFPE samples from a cohort of ER-positive, node-negative breast carcinomas with low, inter-
mediate, and high (19, 21, and 20 cases, respectively) Oncotype DX recurrence scores con-
firmed that patients with high risk of recurrence have lower levels of DLC1 mRNA compared
to low risk cases (Adjusted p = 0.016 using one-way ANOVA-multiple comparisons-GraphPad
Prism 7.03) (Fig 1C). Expression of DLC1 remained non-significant in cases with intermediate
score compared to cases with low scores. These results suggest that low expression of DLC1
Fig 1. Low DLC1 expression is associated with poor prognosis in ER-positive breast cancer. Kaplan-Meier plots using GOBO online analysis (Affymetrix
datasets) as endpoint for 10-year overall survival (OS) in A. ER-positive tumors (p = 0.002), and B. ER-positive and lymph node (LN)-positive tumors (p = 5e-04).
High DLC1 expression was>median; low expression (light grey), and high expression (red) expression. C. qRT-PCR assay showing that DLC1 expression is lower in
patients with High Recurrence Scores in an Oncotype DX cohort n = 60; LS-Low Score, IS-Intermediate Score and HS-High Score. Adjusted p = 0.0160; statistically
significant. D. qRT-PCR analysis showing independent set of lymph node metastatic samples (LNM), and their matched primary tumors (T)(n = 23 matched pairs;
p = 0.2474). The expression values were analyzed according to ΔΔCt method using the Applied Biosystems DataAssist Software v3.0. All FFPE cases were assayed in
duplicates.
https://doi.org/10.1371/journal.pone.0204658.g001
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indicates the likelihood of high recurrence and might contribute to innate resistance in ER-
positive cancers.
The spread of breast tumors to local and regional lymph nodes is an important means of
tumor dissemination. The presence and the number of involved lymph nodes remains the sin-
gle best indicator of whether or not the cancer has become widely metastatic. To further con-
firm the data from the publically available datasets, we performed a comparative analysis of
DLC1 levels in primary tumors and associated nodal metastases. Using qRT-PCR analysis, no
significant difference in DLC1 expression was observed in lymph node metastases compared
with their matched primary breast tumors (n = 23 pairs; p = 0.2474 using Wilcoxon test of sim-
ple one-way ANOVA- GraphPad Prism 7.03;Fig 1D). These results suggest that loss of DLC1
expression may occur at the primary tumor stage rather than in metastatic lesions.
Lack of DLC1 expression is not due to mutations and methylation in
primary breast tumors
To determine the basis of low expression in primary breast tumors, we analyzed the genomic
alterations in The Cancer Genome Atlas (TCGA) breast cancer dataset using the cBioPortal
[20, 21]. Mutations within the coding region were found in ~1% of cases sequenced. These
mutations were not located in the major structure domains associated with the protein func-
tion (Fig 2A). The copy number alterations (CNA) were identified in 7% of patients with
majority being deep deletions (Fig 2B). We next analyzed 737 out of 1104 cases available with
methylation data (HM450). There was poor correlation between RNA expression and methyl-
ation status and/or mutation status (Correlation Pearson: -0.147 and Spearman: -0.221) (Fig
2C). These analyses suggest that downregulation of DLC1 in majority of breast tumors is not
due to mutations or methylation.
Functional impact of DLC1 overexpression in ER+ breast cancer
We next measured the DLC1 mRNA expression levels in ER+ breast cancer cells. Quantitative
reverse transcription- PCR (qRT-PCR) analysis showed that ZR75-1 cells have very low levels
of DLC1, while T-47D cells does not express DLC1 at the detectable levels when compared
with MCF-7 cells (both comparisons having adjusted p = 0.0001 using one-way ANOVA-mul-
tiple comparisons-GraphPad Prism 7.03; Fig 3A). Using Western blot, we also confirmed that
MCF-7 has higher levels of DLC1 compared to T-47D and ZR75.1 cells (Fig 3B) To under-
stand the functional relevance of DLC1 in ER+ breast cancer, we established stable DLC1 over-
expression in T-47D (no endogenous expression of DLC1) cells using GenScript’s GenEZ ORF
cloning technology. The overexpression resulted in dramatic increase in DLC1 mRNA levels
in T-47D cells compared to the T-47D cells expressing control empty vector (DLC1-FL versus
control) using qRT-PCR (Fig 3C). Overexpression of DLC1 in DLC1-FL cells was also con-
firmed at the protein level (p = 0.0001; Fig 3D). Next, we have demonstrated that overexpres-
sion of DLC1 exhibited significant quantitative reduction in colony formation (Fig 3E and
3F). Despite the effect of DLC1 overexpression on cell growth, no changes were observed in
cell cycle, and apoptosis in vitro (S2 Fig). To determine the alterations in invasiveness of the
cells, we employed invasion assay in the presence or absence of serum in collagen 1-coated
plates. This analysis showed a trend towards decreased invasiveness of the DLC1-FL cells (S3
Fig).
Next, we assessed the impact of DLC1 overexpression on RhoA activation. Rho signaling is
important for rearrangement of cancer cell cytoskeleton, which is crucial in cell proliferation
and motility. As shown in Fig 3G, overexpression of DLC1 (DLC1-FL) resulted in decreased
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RhoA activation compared to control cells that lack DLC1, suggesting the Rho-inhibiting
activity of DLC1 in this model.
Proteomic and phosphopeptide analyses
DLC1 can regulate cellular signaling through protein-protein interactions. In particular, DLC1
can be regulated by phosphorylation [14]. In order to better understand the functionality of
full-length DLC1 in ER+ breast cancer, we first performed proteomic analysis of control vector
and DLC1-full-length (DLC1-FL) cells. The reproducibility of global proteome and phospho-
proteome data is demonstrated in scatterplots for replicate samples in S4 and S5 Figs,
Fig 2. Genomic alterations in The Cancer Genome Atlas (TCGA) of breast invasive carcinoma (provisional). A. somatic mutations for DLC1, and B. Copy Number
Alterations (CNA) Data were extracted from the TCGA of breast cancer dataset (BRCA) within the cBioPortal database. In this graphical summary, individual cases
(patients) are represented as columns. C. The datasets used to analyze the methylation pattern at CpG islands using HM450 (Human Methylation 450 BeadChip) assay.
https://doi.org/10.1371/journal.pone.0204658.g002
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Fig 3. Overexpression of DLC1 decreases the colony formation significantly in ER+ breast cancer model. A- B. DLC1
expression in breast cancer cell lines, A. qRT-PCR, B. Western Blot. C-D. Confirmation of stable overexpression of DLC1-full
length (DLC1-FL) expression compared to control vector (control) cells. C. qRT-PCR and D. Western blot. All qRT-PCR and
Western blot assays are done in triplicates. E-F. Clonogenic assay documenting the quantitative decrease in colony formation
in DLC1-FL cells (14 days). G. RhoA activation assay showing decreased RhoA activity in DLC1-FL cells. Calpeptin-activated
RhoA activity is decreased in DLC1-FL compared to control cells. Total RhoA levels are similar in both cells. Representative
data are shown from three separate experiments for clonogenic assay, western Blotting and RhoA activation assay.
https://doi.org/10.1371/journal.pone.0204658.g003
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respectively. A total of 3,073 (96.7%) proteins were identified and quantified in both cell lines,
while only 33 (1%) and 73 (2.3%) proteins were specifically identified and quantified in control
vector cells and DLC1-FL, respectively (Fig 4A). More specifically, of the 397 differentially
expressed proteins, 173 proteins were significantly depleted (FDR-corrected p-value< 0.1,
log2 fold change< -1.0) in the DLC1-FL cells compared to control, whereas 224 proteins were
significantly enriched (FDR-corrected p-value< 0.1, log2 fold change> 1.0) in DLC1-FL com-
pared to control (Fig 4B; S2–S4 Tables). Using the DAVID Functional Annotation Clustering
Tool, we identified the biological processes altered significantly in DLC1-FL overexpression
(Fig 4C; S5 Table). The top three clusters consist of SRP-dependent co-translational protein
targeting to membrane (cluster 1), cell-cell adhesion (cluster 2), and peroxisome signaling
(cluster 3).
Further phosphoproteomic analysis identified 6,726 (95.4%) phosphopeptides that were
identified and quantified in both cell types, while only 205 (2.9%) and 122 (1.7%) phosphopep-
tides were specifically identified and quantified in DLC1-FL and control vector cells, respec-
tively (Fig 4D). Of the 1,301 phosphopeptides differentially quantified, 503 were significantly
depleted (FDR-corrected p-value< 0.1, log2 fold change< -1.0) in DLC1-FL compared to con-
trol and 798 were significantly enriched (FDR-corrected p-value< 0.1, log2 fold change > 1.0)
in DLC1-FL compared to control (Fig 4E; S6–S8 Tables). Of the top three clusters, cluster 1
Fig 4. Label-free quantitative global proteomic and phosphoproteomic profiling of DLC1 overexpressing T-47D breast cancer cells. A. Venn diagram showing the
identified global proteins in DLC1-FL and control cells. B. Volcano plots showing the differential protein expression (FDR-corrected p-value< 0.1) in DLC1-FL versus
control cells. Red triangles represent differentially upregulated proteins, whereas green triangles show the differentially downregulated proteins. C. Pathway analysis
clusters (DAVID) of the significantly altered protein expression in DLC1-FL versus control vector cells. D Venn diagram showing the identified phosphopeptides in
DLC1-FL and control vector cells. E. Volcano plots showing the differential expressed phosphopeptides (FDR-corrected p-value< 0.1) in DLC1-FL versus control
vector cells. Red triangles represent differentially upregulated phosphopeptides, whereas green triangles show the differentially downregulated phosphopeptides. F.
Pathway analysis clusters (DAVID) of the significantly altered phosphopeptides in DLC1-FL versus control vector cells; DLC1-full-length and control vector T-47D cells
were named as DLC1-FL and control, respectively.
https://doi.org/10.1371/journal.pone.0204658.g004
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consists of cell-cell adhesion signaling as expected (Benjamini corrected p<1E-12). Cluster 2
was specific to mRNA splicing and processing. Cluster 3 consisted of transcription regulation
including repression (Fig 4F). Other important clusters have been listed in S9 Table.
Of the top phosphopeptides identified, we have focused on the epithelial cell transforming
sequence 2 (ECT2) due to the availability of the antibody against the phosphopeptide. ECT2, a
guanine nucleotide exchange factor for Rho family GTPases that catalyzes the exchange of
GDP for GTP and activates the Rho GTPases [37]. ECT2 has been reported to be overex-
pressed in a variety of human tumors including breast cancer [38–44]. In the METABRIC
dataset of breast tumors from 1,992 patients, high ECT2 expression was correlated significantly
with poorer survival including all breast cancer subtypes [44]. ECT2 function is regulated by
phosphorylation [33, 45]. In our study, two phosphopeptides (ANTPELK) and (ANTPELKK,
with one missed cleavage) of ECT2 were significantly reduced in DLC1-FL overexpressing cells
compared to control cells (Fig 5A; FDR-corrected p-value< 0.1). A representative mass spec-
trum for each of the identified T359 phosphopeptides has been shown in Fig 5B and 5C. This
phosphopeptide (T359) sequence is identical to the one previously reported as for T328 for a
different isoform of ECT2 [33].
Validation of ECT2 phosphorylation
Using Western blot analysis, we validated the decrease of phosphorylation at T359 as well as
decrease of total protein levels of ECT2 in cells overexpressing DLC1-FL (Fig 5D). The ratio of
the phospho-protein to the total protein showed decreased phospho-protein levels after nor-
malization (S6 Fig). Addition of ECT2 phosphospecific peptide as a competitor during anti-
body incubation completely abolished the bands thereby verifying the specificity of the bands
(data not shown). Together, these data suggest that high DLC1 expression reduces the phos-
phorylation and protein levels of ECT2.
To determine whether our findings in T-47D model are cell-line specific or occur in other
ER+ breast cancer cell lines, we evaluated ECT2 phosphorylation and protein levels in other
ER+ breast cancer cell lines with various endogenous levels of DLC1 expression (Fig 5E).
MCF-7 cells with higher DLC1 expression had the lower ECT2 phosphorylation and total
ECT2 protein expression levels. ZR75.1 cells, as expected, also exhibited a lower level of both
ECT2 phosphorylation and protein levels than T-47D cells. These data confirms that the
inverse association of ECT2 and DLC1 is not cell-line specific and occur in other ER+ models.
These findings are also verified at the mRNA levels (Fig 5F and 5G).
ECT2 phosphorylation in the Clinical Proteomic Tumor Analysis
Consortium (CPTAC) Data
We next compared data from a CPTAC breast cancer phosphoproteomics study [34] to data
from this study. Unique phosphopeptide sequences, which were detected in the CPTAC study
and were significantly changed in our study, are listed along with the matched Uniprot acces-
sion numbers and protein descriptions (S10 Table). Importantly, the ECT2 T359-containing
phosphopeptide was detected in both basal and luminal patient-derived breast cancers.
DLC1 overexpression decreases the expression of primary canonical ER
target proteins independent of ER expression
To determine whether DLC1 overexpression alters the protein levels and the phosphopeptide
levels of ER and endogenous ER targets, we assessed the protein levels of ER, trefoil factor 1/
pS2, cyclin D1, and c-Myc, which are well-characterized ER-regulated genes. No peptides
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from ER, pS2, cyclin D1 or c-Myc were detected in either the global or the phospho-enriched
samples in control or DLC1-FL cells. This is not surprising due to the untargeted approach
that we utilized and the low levels of these proteins in the cells. Furthermore, progesterone
receptor protein and phosphorylation levels were unchanged in DLC1-FL compared to control
cells (FDR corrected p-values > 0.83)(S7 Fig).
We further analyzed the protein levels expression of the above ER targets using Western
blotting analysis. We demonstrated that DLC1 overexpression decreased the protein expres-
sion of trefoil factor 1/pS2, cyclin D1, and c-Myc, although these were not detectable from
Fig 5. Decrease of ECT2 phosphorylation at T359 residue in DLC1 overexpressing cells. A. Significant decrease in two phosphopeptides
(ANTPELK) and (ANTPELKK, with one missed cleavage) in DLC1-FL overexpressing cells compared to control vector cells (FDR-corrected p-
value< 0.1). B-C. Phosphopeptide quantification by label-free LC-MS/MS. Representative mass spectra for each of the identified T359
phosphopeptides. D. Independent Western blot validation of ECT2 phosphorylation with phosphosite-specific and total protein antibodies in
DLC1-FL and control vector cells (see details in “Materials and Methods”). A549 human lung carcinoma cell line was used as positive control for
ECT2 phosphorylation and total protein levels. Antibody against β-actin was used as reference (loading control); p-ECT2 represents phospho
ECT2 specific to T359 residue (Uniprot sequence identifier for isoform 2: Q9H8V3-2). E. ECT2 phosphorylation (T359) and total protein levels
in ER+ breast cancer cell lines. F. ECT2 mRNA levels of control and DLC1-FL overexpressing cells using qRT-PCR. G. ECT2 mRNA levels of ER
+ breast cancer cell lines using qRT-PCR assay.
https://doi.org/10.1371/journal.pone.0204658.g005
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proteomics data (Fig 6). However, the ER levels were not changed in both control and
DLC1-FL cells. Phospho-ER levels were not at the detectable level in Western blotting (data
not shown). These data suggests the effect of DLC1 in ER targets by mechanisms that are inde-
pendent of ER.
Discussion
In this study, we evaluated the expression and prognostic relevance of DLC1 in breast cancer
as well as its cellular interaction via phosphopeptide analysis in breast cancer. Our analyses
revealed that high expression of DLC1 correlated with longer overall survival (OS) in ER-posi-
tive, but not ER-negative patients. Of note, the association of low DLC1 expression with poor
outcome was prominent even in node-positive tumors.
Expression of DLC1 is silenced in human gastric cancer [46], prostate cancer [7], multiple mye-
loma [47] and leukemia [48] cell lines. Our analysis of genomic alterations using TCGA revealed
that downregulation or loss of DLC1 is not due to copy number alterations (CNAs) or the muta-
tions. This suggests that silencing of DLC1 might be due to the epigenetic mechanisms. Hyper-
methylation of DLC1 promoter has also been shown to be responsible for inactivating DLC1 gene
in various solid tumors [6, 9, 49] albeit in varying frequencies. Seng et al[6] reported that DLC1
was methylated in 5 out of 14 (36%) primary breast carcinomas while Teramoto et al[49] found it
to be is less frequent (10%). In concordance with the latter study, our analysis of TCGA breast
dataset showed a methylation in 6% (44/737) of breast tumors. These findings suggest the contri-
bution of other mechanisms such as transcriptional repression needs to be explored.
Dai et al recently reported that tumors with high DLC1 and low CDK6 expression were
associated with good prognosis[50]. Although this study determined the relevance of DLC1 in
breast cancer within a subset population of CDK6 interaction, our study suggests the impor-
tance of DLC1 in ER-positive breast cancer regardless of other factors. In their analysis of the
TCGA dataset, they did not identify a strong prognostic impact for DLC1. The differences in
the two studies could be due a number of factors including the limitations of treatment and
follow-up information within the TCGA cohort.
In order to obtain additional insights into DLC1 function, we decided to study the protein-
protein interactions. Phosphorylation is an important posttranslational modification that can
determine the functional significance of the protein expression. Changes in the phosphopro-
teome can provide an insight into the regulation of the proteins. In our study, we applied a
phosphopeptide enrichment analysis using full-length DLC1 in comparison with the control
cells lacking DLC1 to identify altered phosphorylated peptides. This approach revealed the
involvement of DLC1 in expected processes such as cell-cell adhesion as well as novel biologi-
cal processes including mRNA processing. These data further opens new avenues to under-
stand the DLC1 network in this cancer.
The differentially expressed phosphopeptides included ECT2, which has been documented
to have multiple functions including cell cycle and ribosomal biogenesis [45, 51, 52]. We have
identified the downregulation of the phosphopeptide corresponding to T359 of ECT2 in
DLC1-FL cells validated using Western blotting. The specific sequence of this site (ANTPELK)
has previously been shown to be phosphorylated by PKCι-Par6 at the T328 residue of ECT2
by the Justilien et al [33]. The phosphopeptide sequence for T328 is identical to the T359. The
difference in the phosphosites could be due to an isoform difference. T359 corresponds to
isoform 2 (Uniprot sequence identifier for isoform 2: Q9H8V3-2), whereas isoform 1 corre-
sponds to T328. The comparison of the cell line with CPTAC confirmed ECT2 phosphopep-
tide in patient derived xenografts (PDXs) of breast cancers [34]. This is the first time, that
ECT2 phosphorylation has been directly implicated in breast cancer. The importance of this
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phosphorylation site has been previously documented in lung cancer and proposed as a target
for therapeutics [52].
In support our data, a recent study reported that several cancer types are associated with
increased expression and activity of the ECT2 RhoGEF and decreased expression and activity
of the DLC1 RhoGAP, leading to increased RhoA activity [53]. Using the TCGA and CPTAC
databases, they examined the relationship between DLC1 and ECT2 and supported our find-
ings in this study. Indeed, they also stated that the combination of high ECT2 expression and
low DLC1 expression level is more common in poorly differentiated tumors than in well dif-
ferentiated ones. Together, both studies suggest that ECT2 and DLC1 frequently act together,
but in opposite directions, in cancer to increase RhoA activity. Interestingly, our data also sug-
gests the effect of DLC1 on ER targets independent of ER expression.
In conclusion, our study suggests a role of DLC1 in prognosis of ER-positive breast cancer.
DLC1 decreased the expression of primary canonical ER target proteins independent of ER
expression. Furthermore, our phosphoproteomic analysis, for the first time, demonstrated an
inverse correlation with high DLC1 expression and lower phosphorylation of ECT2 in breast
cancer. Further analyses are necessary to determine the potential targeting of ECT2 in breast
cancers with low DLC1 expression.
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